Cost-effectiveness of antenatal HIV-testing: reviewing its pharmaceutical and methodological aspects

Bibliography

• THE INTERNATIONAL PERINATAL HIV GROUP: The mode of delivery and the risk of vertical transmission of human immunodeficiency virus Type 1. N Engl.aMed. (1999) 340:977–987.
   PubMed Web of Science ®Google Scholar
• DUNN DT, NEWELL ML, ADES AE, PECKHAM CS: Risk of human immunodeficiency virus Type 1 transmission through breastfeeding. Lancet (1992) 340:585–588.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Public Health Service task force recommendations for the use of antiretroviral drugs inpregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. (1998) 47:RR–2.
   Google Scholar
• CENTERS FOR DISEASE CONTROLAND PREVENTION (CDC): Revised guidelines for HIV counselling, testing, and referral and revised recommendations for HIV screening of pregnant women. (2001) 50:RR–19.
   Google Scholar
• CENTERS FOR DISEASE CONTROLAND PREVENTION (CDC): Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. recommendations of the panel on clinical practices for treatment of HIV. (2002) 51:RR–7.
   Google Scholar
• THE ITALIAN REGISTER FOR HUMAN immunodeficiency virusainfection in children: determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch. Pediatr. Adelesc. Med. (2002) 156:915–921.
   PubMedGoogle Scholar
• VAN ROSSUM AM, KUIPER IE, RODRIGUES PR, SCHERPBIER HJ, WOLFS TF, DE GROOT R: Reduction of vertical transmission by means of perinatal prophylaxis in the case of children exposed to HIV-1 and born in the Netherlands during the period 1995 — 1999. Ned. Tljdschr. Geneeskd (2002) 146:1277–1281.
   PubMedGoogle Scholar
• LORENZI P, SPICHER VM, LAUBEREAU B et al: Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS (1998) 12:F241–F247.
   Google Scholar
• BRINKMAN K, TER HOFSTEDE HJ,BURGER DM et al.: Adverse effects of reverse transcriptase inhibitors; mitochondrial toxicity as common pathway. AIDS (1998) 12:1735–1744.
   Google Scholar
• BLANCHES, TARDIEU M, RUSTIN P et al.: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet (1999) 354:1084–1089.
   PubMed Web of Science ®Google Scholar
• THE PERINATAL SAFETY REVIEW WORKING GROUP: Nucleoside exposure in the children of HIV-infected Women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. Acquir. Immune Defic. Syndr. (2000) 25:261–268.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Revised Recommendations for HIV Screening of Pregnant Women. MMWR Morb. Mortal. Wkly. Rep. (2001) 50(RR19):59–86.
   Google Scholar
• WORLD HEALTH ORGANISATION: Wkly. Epidennol Rec. (1992) 20:145–152.
   Google Scholar
• CONNOR EM, SPERLING RS, GELBER R et al.: Reduction of maternal-infant transmission of human immunodeficiency virus Type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl. J. Med. (1994) 331:1173–1180.
   Google Scholar
• HOUSHYAR A: Screening pregnant women for HIV-antibody: cost-benefit analysis. AIDS Public Policy" (1991) 6:98–103.
   PubMedGoogle Scholar
• LE GALES C, MOATTI JP and the PARIS-TOURS STUDY GROUP OF ANTENATAL TRANSMISSION OF HIV, GROUP '9 MATERNITES': Cost-effectiveness of HIV screening of pregnant women in hospitals of the Paris area. Ear: I Obstet. Cynecol. Reprod. Biol. (1990) 37:25–33.
   Google Scholar
• BINDELS PJE, ON BEHALF OF THE WORKING GROUP: Resultaten van de screening op HIV-antistoffen bij Zwangere vrouwen, Bezoeksters van Infertifiteitspoliklinieken en Abortuskfinieken in de Regio Amsterdam in 1990. Ned. Tljdschr. Geneeskd. (1991) 135:2123–2128.
   PubMedGoogle Scholar
• BUECKERT H: Costs and benefits of screening pregnant women for HIV. Can. Med. Assoc. J. (1996) 10:1387.
   Google Scholar
• MYERS ER, THOMPSON JW, SIMPSON K: Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. Obstet. CynaecoL (1998) 91:174–181.
   Google Scholar
• WILKINSON D, WILKINSON N, LOMBARD C et al: On-site HIV testing in resource-poor settings: is one rapid test enough? AIDS (1997) 11:377–381.
   PubMed Web of Science ®Google Scholar
• MANSERGH G, HADDIX AC,STEKETEE RW et al.: Cost-effectiveness of short-course zidovudine to prevent perinatal HIV Type 1 infection in a Sub-Saharan African developing country setting. JA/VIA (1996) 276:139–145.
   Google Scholar
• RATCLIFFE J, ADES AE, GIBB D, SCULPHER MJ, BRIGGS AH: Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness. AIDS (1998) 12:1381–1388.
   PubMedGoogle Scholar
• ECKERJL: The cost-effectiveness of human immunodeficiency virus screening in pregnancy. Am. J. Obstet. Cynecol. (1995) 174:716–721.
   Google Scholar
• RIVERA-ALSINA MA, RIVERA CC, ROLLENE N, KIRBY RS, AYES A, MCNAMARA M: Voluntary Screening Program for HIV in Pregnancy: cost effectiveness. .1 Reprod. Med. (2001) 46:243–248.
   Google Scholar
• STRINGER JSA, ROUSE DJ: Rapid Testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: a cost-effectiveness analysis. Obstet. Gynecol (1999) 94:34–40.
   PubMedGoogle Scholar
• PATRICK DM, MONEY DM, FORBES J et al.: Routine prenatal screening for HIV in a low-prevalence setting. Can. Med. Assoc. J. (1998) 159:942–947.
   Google Scholar
• GORSKY RD, FARNHAM PG, STRAUS WL et al.: Preventing perinatal transmission of HIV - costs and effectiveness of a recommended intervention. Public Health Rep. (1996) 111:335–341.
   PubMed Web of Science ®Google Scholar
• BRAMLEY D, GRAVES N, WALKER D: The cost-effectiveness of universal antenatal screening for HIV in New Zealand. AIDS(2003) 17:741–748.
   PubMedGoogle Scholar
• POSTMA MJ, BECK EJ, HANKINS CA et al.: Cost effectiveness of expanded antenatal HIV testing in London. AIDS(2000) 14:2383–2389.
   PubMed Web of Science ®Google Scholar
• ••The only study of economics of expanded antenatal testing.
   Google Scholar
• POSTMA MJ, VAN DEN HOEK JAR, BECK EJ, HEEG B, JAGER JC, COUTINHO RA: Pharmaco-economic evaluation of universal HIV-screening of pregnant women; a cost-effectiveness analysis for Amsterdam. Ned. Tljdschr. Geneeskd (2000) 144:749–754.
   PubMedGoogle Scholar
• IMMERGLUCK LC, CULL WL, SCHWARTZ A, ELSTEIN AS: Cost-Effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics (2000) 105:E45.
   Google Scholar
• ZARIC GS, BAYOUMI AM,BRANDEAU ML, OWENS DK: The cost effectiveness of voluntary prenatal and routine newborn screening in the United States. J. AIDS (2000) 25:403–416.
   PubMedGoogle Scholar
• POSTMA MJ, BECK EJ, MANDALIA S et al.: Universal HIV screening of pregant women in England: cost effectiveness analysis. Br. Med. J. (1999) 318:1656–1660.
   PubMed Web of Science ®Google Scholar
• •One of two landmark studies.
   Google Scholar
• ADES AE, SCULPHER MJ, GIBB DM, GUPTA R, RATCLIFFE J: Cost effectiveness analysis of antenatal HIV screening in United Kingdom. Br. Med. J. (1999) 319:1230–1234.
   PubMedGoogle Scholar
• •One of two landmark studies.
   Google Scholar
• SODERLAND N, ZWI K,KINGHORN A, GRAY G: Prevention of verical transmission of HIV: analysis of cost effectiveness of options available in South Africa. Br. Med. J. (1999) 318:1650–1656.
   PubMedGoogle Scholar
• MARSEILLE E, KAHN JG, MMIRO F et al.: Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet (1999) 354:803–809.
   PubMed Web of Science ®Google Scholar
• ••One of only a few studies in developingcountries.
   Google Scholar
• MARSEILLE E, KAHN JG, SABA J: Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS (1998) 12:939–948.
   PubMed Web of Science ®Google Scholar
• MAUSKOPF JA, PAUL JE,WICHMAN DS et al: Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. JAMA (1996) 276:132–138.
   PubMedGoogle Scholar
• LAUPACIS A, FEENY D, DETSKY AS, TUGWELL PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can. Med. Assoc. J. (1992) 146:473–481.
   PubMed Web of Science ®Google Scholar
• OWENS DK: Interpretation of cost-effectiveness analyses. Gen. Intern. Med. (1998) 13:716–717.
   PubMed Web of Science ®Google Scholar
• ADES AE, RATCLIFFE J, GIBB DM, SCULPHER MJ: Economic Issues in the Prevention of Vertical Transmission of HIV. Pharmacoeconomics (2000) 18:9–22.
   PubMedGoogle Scholar
• ••A previous review on the topic.
   Google Scholar
• GIBB DM, ADES AE, GUPTA R, SCULPHER MJ: Costs and benefits to the mother of antenatal HIV testing: estimates from simulation modelling. AIDS (1999) 13:1569–1576.
   PubMedGoogle Scholar
• SWEAT M, GREGORICH S,SANGIWA G et al: Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet (2000) 356:113–121.
   PubMed Web of Science ®Google Scholar
• URNOVITZ HB, STURGE JC, GOTTFRIED TD, MURPHY WH: Urine antibody tests: new insights into the dynamics of HIV-1 infection. Clin. Chem. (1999) 45:1602–1613.
   PubMedGoogle Scholar
• KOBLAVO-DEME S, MAURICE C, YAVO Vet al: Sensitivity and specificity ofhuman immunodeficiency virus rapid serological assays and testing algorithms in an antenatal clinic in Abidjan, Ivory Coast. Clin. Microbiol (2001) 39:1808–1812.
   Google Scholar
• HJELMGREN J, BERGGREN F,ANDERSSON F: Health economic guidelines — similarities, differences and some implications. Value in Health (2001) 4:225–250.
   PubMedGoogle Scholar
• •State of the art in health economic guideline development.
   Google Scholar
• POSTMA MJ, BECK EJ,SPRENGER HG,DE JONG — VAN DEN BERG LTW: The Economic Profile of Antenatal HIV-testing: pharmaceutical and methodological considerations. AIDS (2003) 17:755-757 (Editorial).
   Google Scholar
• VAN HOUT BA: Discounting costs and effects: a reconsideration. Health Econ. (1998) 7:581–594.
   PubMed Web of Science ®Google Scholar
• GRAVELLE H, SMITH DH: Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ. (2001) 10:587–599.
   PubMed Web of Science ®Google Scholar
• BOS JM, ANNEMANS L, BEUTELS P,POSTMA MJ: Valuing prevention through economic evaluation: some considerations regarding the choice of the discount model for health effects. Pharmacoeconomics (Accepted).
   Google Scholar
• http://www.aidsinfo.nih.gov/US Public Health Service: Recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the US.
   Google Scholar
• http://www.who.int/bct/Main_areas_of_work/ BTS/HIV_Diagnostics/Overview_of HIV_ Diagnostic_Tech.htmAn overview of HIV diagnostic technologies.
   Google Scholar
• http://www.nice.uk
   Google Scholar